These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 33866913)

  • 41. The combination of hyper-CVAD plus nelarabine as frontline therapy in adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma: MD Anderson Cancer Center experience.
    Jain P; Kantarjian H; Ravandi F; Thomas D; O'Brien S; Kadia T; Burger J; Borthakur G; Daver N; Jabbour E; Konopleva M; Cortes J; Pemmaraju N; Kelly MA; Cardenas-Turanzas M; Garris R; Faderl S
    Leukemia; 2014 Apr; 28(4):973-5. PubMed ID: 24157581
    [No Abstract]   [Full Text] [Related]  

  • 42. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
    Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
    Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
    [No Abstract]   [Full Text] [Related]  

  • 43. Fatal neurological side-effects with necrosis of spinal cord following nelarabine treatment in a child with relapsed T-cell acute lymphoblastic leukemia.
    Hartz B; Löbel U; Hagel C; Escherich G
    Am J Hematol; 2013 Dec; 88(12):1096-7. PubMed ID: 23873785
    [No Abstract]   [Full Text] [Related]  

  • 44. Pegaspargase, venetoclax, and nelarabine: a successful bridge to allogeneic hematopoietic stem cell transplantation in a relapsed/refractory T-cell acute lymphoblastic leukemia patient.
    Yiğit Kaya S; Bektas S; Askin AE; Balık Aydın B; Mutlu YG; Sevindik ÖG
    Ann Hematol; 2023 Jun; 102(6):1599-1600. PubMed ID: 37099080
    [No Abstract]   [Full Text] [Related]  

  • 45. Nelarabine.
    Sanford M; Lyseng-Williamson KA
    Drugs; 2008; 68(4):439-47. PubMed ID: 18318562
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic strategies, including allogeneic stem cell transplantation, to overcome relapsed/refractory adult T-cell acute lymphoblastic leukemia.
    Baek DW; Lee JM; Kim J; Cho HJ; Moon JH; Sohn SK
    Expert Rev Hematol; 2021 Aug; 14(8):765-775. PubMed ID: 34313508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
    Iino M
    Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
    Reilly KM; Kisor DF
    Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Approval summary: nelarabine for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Massie T; Sridhara R; McGuinn WD; Abraham S; Booth BP; Goheer MA; Morse D; Chen XH; Chidambaram N; Kenna L; Gobburu JV; Justice R; Pazdur R
    Clin Cancer Res; 2006 Sep; 12(18):5329-35. PubMed ID: 17000665
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nelarabine neurotoxicity with concurrent intrathecal chemotherapy: Case report and review of literature.
    Ngo D; Patel S; Kim EJ; Brar R; Koontz MZ
    J Oncol Pharm Pract; 2015 Aug; 21(4):296-300. PubMed ID: 24664478
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434.
    Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP
    Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene expression ratio as a predictive determinant of nelarabine chemosensitivity in T-lymphoblastic leukemia/lymphoma.
    Sripornsawan P; Okamoto Y; Nishikawa T; Kodama Y; Yamaki Y; Kurauchi K; Tanabe T; Nakagawa S; Shinkoda Y; Imuta N; Kawano Y
    Pediatr Blood Cancer; 2017 Feb; 64(2):250-253. PubMed ID: 27576612
    [TBL] [Abstract][Full Text] [Related]  

  • 53. MR imaging in nelarabine-induced myelopathy.
    Dua SG; Jhaveri MD
    J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nelarabine in the treatment of refractory T-cell malignant diseases.
    Kline J; Larson RA
    Expert Opin Pharmacother; 2006 Sep; 7(13):1791-9. PubMed ID: 16925505
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacotherapeutic management of T-cell acute lymphoblastic leukemia in adults: an update of the literature.
    Grunenberg A; Sala E; Kapp-Schwoerer S; Viardot A
    Expert Opin Pharmacother; 2022 Apr; 23(5):561-571. PubMed ID: 35193450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine.
    Kawakami M; Taniguchi K; Yoshihara S; Ishii S; Kaida K; Ikegame K; Okada M; Watanabe S; Nishina T; Hamada H; Nakagawa M; Ogawa H
    Am J Hematol; 2013 Oct; 88(10):853-7. PubMed ID: 23757212
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapsed T Cell ALL: Current Approaches and New Directions.
    McMahon CM; Luger SM
    Curr Hematol Malig Rep; 2019 Apr; 14(2):83-93. PubMed ID: 30880359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
    McGregor BA; Brown AW; Osswald MB; Savona MR
    Am J Hematol; 2009 Apr; 84(4):228-30. PubMed ID: 19260120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.